GEMPのチャート
GEMPの企業情報
| symbol | GEMP |
|---|---|
| 会社名 | Gemphire Therapeutics Inc （ジェムフィア―・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ジェムフィアー･セラピューティクス(Gemphire Therapeutics Inc)は脂質異常症治療法の気あは開発･商業化事業に従事する臨床段階バイオ医薬品会社である。開発中の製品候補Gemcabene (CI-1027)はスタチン療法等の承認済治療法によって低密度リポタンパク質コレステロール(LDL-C)またはトリグリセリドの正常レベル達成困難な患者向けの一日一回の経口療法である。Gemcabeneは家族性高コレステロール血症(HeFH)、アテローム性動脈硬化心血管疾患(ASCVD)及び重度の高トリグリセリド血症(SHTG)向けに開発される。Gemcabeneの作用メカニズムは血漿中の超低密度リポタンパク質(VLDLs)の除去の改善及び肝臓中の脂肪酸とコレステロールの産出の阻害のために設計される。Gemcabeneは約20の第I相･第II相臨床試験にわたり、単剤療法及びスタチンと他の薬剤との組み合わせとしてテストされる。 ジェムフィア―・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、主に心血管疾患の危険性を増す脂質異常症に対する治療法の開発・商業化に従事する。脂質異常症は血中の悪玉コレステロ―ル(LDL-C)や中性脂肪などの脂質が増加する状態で、同社経口薬ジェムカベン(CI-1027)は治療薬の1つ。本社はミシガン州ノ―スビル。 Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. |
| 本社所在地 | 17199 N. Laurel Park Drive Suite 401 Livonia MI 48152 USA |
| 代表者氏名 | Charles L. Bisgaier チャールズ・L・ビスガール |
| 代表者役職名 | Chairman of the Board Chief Scientific Officer |
| 電話番号 | +1 734-245-1700 |
| 設立年月日 | 39753 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | － |
| url | www.gemphire.com |
| nasdaq_url | https://www.nasdaq.com/symbol/gemp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -28.70400 |
| 終値（lastsale） | 2.11 |
| 時価総額（marketcap） | 30100017.21 |
| 時価総額 | 時価総額（百万ドル） 20.39954 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2.55254 |
| 当期純利益 | 当期純利益（百万ドル） -29.31900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Gemphire Therapeutics Inc revenues was not reported. Net loss decreased 23% to $13.9M. Lower net loss reflects Other expense decrease from $5K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$1.78 to -$1.05. |
GEMPのテクニカル分析
GEMPのニュース
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout 2019/10/11 12:14:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences …
The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave 2019/09/27 11:56:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept.
The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J 2019/09/26 11:54:44 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 25.) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) ( announced lackadaisical efficacy data for pancreatic insufficiency drug) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Exagen Inc (NASDAQ: XGN ) (IPOed on Sep. 16) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Novelion Therapeutics Inc (NASDAQ: NVLN ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics Inc (NASDAQ: ONTX ) PDS Biotechnology Corp (NASDAQ: PDSB ) Plus Therapeutics Inc (NASDAQ: PSTV ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sophiris Bio Inc (NASDAQ: SPHS ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Tocagen Inc (NASDAQ: TOCA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Urogen Pharma Ltd (NASDAQ: URGN ) Vaxart Inc (NASDAQ: VXRT ) (announced positive topline results for an early-stage …
The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris 2019/09/10 11:36:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency.
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books 2019/09/04 11:08:03 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results from a late-stage of its lead compound tenapanor in combination with phosphate binders to treat hyperphosphatemia in patients with chronic kidney disease on dialysis) China Biologic Products Holdings Inc (NASDAQ: CBPO ) DURECT Corporation (NASDAQ: DRRX ) Insulet Corporation (NASDAQ: PODD ) ( announced private offering of convertible senior notes) Lipocine Inc (NASDAQ: LPCN ) NextCure Inc (NASDAQ: NXTC ) The Medicines Company (NASDAQ: MDCO ) (announced positive Phase 3 results for inclisiran) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 3) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aduro BioTech Inc (NASDAQ: ADRO ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Assembly Biosciences Inc (NASDAQ: ASMB ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) (announced completion of dose-escalation part of the Phase 1/2a study of AGI-134) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Gemphire Therapeutics Inc (NASDAQ: …
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout 2019/10/11 12:14:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences …
The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave 2019/09/27 11:56:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept.
The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J 2019/09/26 11:54:44 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 25.) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) ( announced lackadaisical efficacy data for pancreatic insufficiency drug) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Exagen Inc (NASDAQ: XGN ) (IPOed on Sep. 16) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Novelion Therapeutics Inc (NASDAQ: NVLN ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics Inc (NASDAQ: ONTX ) PDS Biotechnology Corp (NASDAQ: PDSB ) Plus Therapeutics Inc (NASDAQ: PSTV ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sophiris Bio Inc (NASDAQ: SPHS ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Tocagen Inc (NASDAQ: TOCA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Urogen Pharma Ltd (NASDAQ: URGN ) Vaxart Inc (NASDAQ: VXRT ) (announced positive topline results for an early-stage …
The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris 2019/09/10 11:36:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency.
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books 2019/09/04 11:08:03 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results from a late-stage of its lead compound tenapanor in combination with phosphate binders to treat hyperphosphatemia in patients with chronic kidney disease on dialysis) China Biologic Products Holdings Inc (NASDAQ: CBPO ) DURECT Corporation (NASDAQ: DRRX ) Insulet Corporation (NASDAQ: PODD ) ( announced private offering of convertible senior notes) Lipocine Inc (NASDAQ: LPCN ) NextCure Inc (NASDAQ: NXTC ) The Medicines Company (NASDAQ: MDCO ) (announced positive Phase 3 results for inclisiran) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 3) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aduro BioTech Inc (NASDAQ: ADRO ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Assembly Biosciences Inc (NASDAQ: ASMB ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) (announced completion of dose-escalation part of the Phase 1/2a study of AGI-134) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Gemphire Therapeutics Inc (NASDAQ: …